Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

compulsory licence

EU flag

CHMP backs orphan drugs Uptravi and Coagadex

EMA advisors set Actelion and Bio Products therapies on path to European approval

- PMLiVE

Roche’s Silvia Ayyoubi retires

She will step down in March as head of group human resources

EU flag

EMA unveils draft guidelines for Alzheimer’s disease research

Puts plans for evaluating potential new therapies out for consultation

Roche Basel Switzerland

Roche shares slip as profits miss expectations

But shows solid sales growth thanks to its oncology portfolio

National Institute for Health and Care Excellence NICE logo

NICE backs BMS’ Opdivo for melanoma

Recommendation comes despite the Institute rejecting the drug for lung cancer

EISAI

Eisai’s Lenvima gets FDA priority review for kidney cancer

The oncology treatment could now be approved in the US before the summer

- PMLiVE

Merck & Co buys IOmet to boost immuno-oncology tech

Reports suggest it paid up to £280m for the Scottish biopharma company

Roche Basel Switzerland

AbbVie and Roche hoping for speedy venetoclax approval

Leukaemia treatment could reach US and EU markets within months

- PMLiVE

Mylan buys into six biosimilars, including Orencia candidate

Deal with Momenta bolsters biosimilars pipeline for new products

Roche Basel Switzerland

Roche prepares to file atezolizumab for bladder cancer

Imminent submission to the FDA after additional positive phase II trial results

Roche nominates Dr Claudia Süssmuth Dyckerhoff to board

She is set to replace Professor Dr Beatrice Weder di Mauro

- PMLiVE

Keytruda bounces back in rivalry with Opdivo

First drug in its class to secure FDA approval as a first-line therapy for malignant melanoma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links